Physician profile
Manjunath Vadmal
NPI 1043228083
$56,716.03
in general payments reported to CMS, 2019-2025
44 companies · $4,321 in 2025
The $4,321 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,753 · 2021: $3,805 · 2022: $6,372 · 2023: $11K · 2024: $12K · 2025: $4,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $11K · Travel and Lodging: $2,128 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,416.94 |
| Consulting Fee | $10,830.00 |
| Travel and Lodging | $2,128.22 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,059.37 | 2019-2025 | |
| Dermavant Sciences, INC. | $10,108.83 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $4,808.05 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Leo Pharma INC. | $4,542.84 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Abbvie INC. | $2,394.59 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $2,295.43 | 2019-2025 | |
| Promius Pharma LLC | $2,174.23 | 2019 | |
| Arcutis Biotherapeutics, INC. | $1,993.98 | 2023-2025 | Zoryve |
| Ucb, INC. | $1,793.34 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,599.28 | 2019-2025 | Winlevi, Ilumya, Odomzo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,413.78 | 2019-2025 | Siliq, Duobrii, Arazlo |
| Organon LLC | $1,384.02 | 2024-2025 | Vtama |
| Amgen INC. | $1,244.95 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,072.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $925.82 | 2022-2025 | Sotyktu |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjunath Vadmal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.